Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Comorbidities

Glucocorticoids and osteoporosis: predicting fracture risk

Nature Reviews Rheumatology volume 6, pages 681–682 (2010)Cite this article

Subjects

The link between glucocorticoid use and bone loss, with increased fracture risk, necessitates care in prescribing these potent anti-inflammatory drugs. What impact will new ACR recommendations—incorporating new clinical trial data and modern methodology for guideline development—have on ensuring that patients receive proper management to reduce the negative impact of glucocorticoids on bone health?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Grossman, J. M. et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. (Hoboken) doi:10.1002/acr.20295.

  2. [No authors listed] Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 44, 1496–1503 (2001).

  3. van Staa, T. P. et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 98, 191–198 (2005).

    Article  Google Scholar 

  4. Reid, D. M. et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373, 1253–1263 (2009).

    Article  CAS  Google Scholar 

  5. Saag, K. G. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 357, 2028–2039 (2007).

    Article  CAS  Google Scholar 

  6. Shekelle, P. The appropriateness method. Med. Decis. Making 24, 228–231 (2004).

    Article  Google Scholar 

  7. Kanis, J. A. et al. FRAX and its applications to clinical practice. Bone 44, 734–743 (2009).

    Article  Google Scholar 

  8. van Staa, T. P. et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 48, 3224–3229 (2003).

    Article  CAS  Google Scholar 

  9. Curtis, J. R. et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum. 52, 2485–2494 (2005).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Dallas, 75231, Texas, USA

    Stanley B. Cohen

Authors
  1. Stanley B. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cohen, S. Glucocorticoids and osteoporosis: predicting fracture risk. Nat Rev Rheumatol 6, 681–682 (2010). https://doi.org/10.1038/nrrheum.2010.194

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2010.194

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing